[SCHEDULE 13G] Latigo Biotherapeutics, Inc. Passive Investment Disclosure (>5%)
Latigo Biotherapeutics 5% stake held by Blavatnik group
Latigo Biotherapeutics, Inc. (LTGO) is reported to have 63,238,030 shares of common stock outstanding immediately following its initial public offering, as described in a prospectus filed under Rule 424(b)(4) on August 7, 2026.
Latigo Biotherapeutics, Inc. (LTGO) is reported to have 63,238,030 shares of common stock outstanding immediately following its initial public offering, as described in a prospectus filed under Rule 424(b)(4) on August 7, 2026. A group consisting of AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik reports beneficial ownership of 3,185,177 shares of Latigo common stock, representing 5.0% of the outstanding shares. These shares are held directly by AI Biotechnology LLC, with the other reporting persons deemed to share voting and dispositive power through their control relationships. Each reporting person other than AI Biotechnology, and related affiliates and officers, disclaims beneficial ownership beyond their pecuniary interest.
Shares outstanding63,238,030 sharesCommon stock outstanding immediately following Latigo Biotherapeutics’ initial public offering
Shares beneficially owned3,185,177 sharesLatigo common shares held directly by AI Biotechnology LLC and reported by the group
Ownership percentage5.0%Percentage of Latigo Biotherapeutics common stock reported as beneficially owned by the group
Key Terms
beneficially owned, shared voting power, shared dispositive power, initial public offering, +2 more
6 terms
beneficially ownedfinancial
"Amount beneficially owned: See the responses to Item 9 on the attached cover pages."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerfinancial
"Shared Voting Power 3,185,177.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 3,185,177.00"
initial public offeringfinancial
"shares of Common Stock outstanding immediately following the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
Rule 424(b)(4)regulatory
"as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4)"
Schedule 13Gregulatory
"executes this pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Latigo Biotherapeutics (LTGO) does the reporting group own?
The reporting group states beneficial ownership of 5.0% of Latigo Biotherapeutics’ common stock, based on 3,185,177 shares out of 63,238,030 shares outstanding immediately after the company’s initial public offering as described in its August 7, 2026 prospectus.
How many Latigo Biotherapeutics (LTGO) shares are beneficially owned by AI Biotechnology LLC and affiliates?
The group led by AI Biotechnology LLC reports beneficial ownership of 3,185,177 shares of Latigo common stock. This stake is calculated against 63,238,030 shares outstanding following Latigo’s IPO, resulting in a reported 5.0% ownership position in the company.
Who are the reporting persons in this Schedule 13G for Latigo Biotherapeutics (LTGO)?
The reporting persons are AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik. They report beneficial ownership of the same 3,185,177 shares, held directly by AI Biotechnology LLC, with shared voting and dispositive power.
What is the basis for the 5.0% ownership calculation in Latigo Biotherapeutics (LTGO)?
The 5.0% ownership is calculated using 63,238,030 shares of Latigo common stock outstanding immediately following its IPO. This outstanding share count comes from Latigo’s prospectus filed under Rule 424(b)(4) with the SEC on August 7, 2026.
Does Len Blavatnik have sole or shared voting power over Latigo Biotherapeutics (LTGO) shares?
The filing reports 0 shares of sole voting power and 3,185,177 shares of shared voting power for Len Blavatnik. The same 3,185,177 shares are also reported as subject to shared dispositive power through the control structure described.
Are all reporting persons deemed to beneficially own the same Latigo Biotherapeutics (LTGO) shares?
Yes. The same 3,185,177 shares held directly by AI Biotechnology LLC may be deemed beneficially owned by Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik due to control relationships, though each disclaims beneficial ownership beyond their interest.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Latigo Biotherapeutics, Inc.
(Name of Issuer)
Common stock, par value $0.0001 per share
(Title of Class of Securities)
517954103
(CUSIP Number)
08/11/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
517954103
1
Names of Reporting Persons
AI Biotechnology LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,185,177.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,185,177.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,185,177.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission (the "SEC") on August 7, 2026.
SCHEDULE 13G
CUSIP Number(s):
517954103
1
Names of Reporting Persons
Access Industries Holdings LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,185,177.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,185,177.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,185,177.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 7, 2026.
SCHEDULE 13G
CUSIP Number(s):
517954103
1
Names of Reporting Persons
Access Industries Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,185,177.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,185,177.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,185,177.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 7, 2026.
SCHEDULE 13G
CUSIP Number(s):
517954103
1
Names of Reporting Persons
Len Blavatnik
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,185,177.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,185,177.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,185,177.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 7, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Latigo Biotherapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA 91320
Item 2.
(a)
Name of person filing:
AI Biotechnology LLC
Access Industries Holdings LLC ("AIH")
Access Industries Management, LLC ("AIM")
Len Blavatnik
(b)
Address or principal business office or, if none, residence:
The principal business office of each reporting person is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.
(c)
Citizenship:
Each of AI Biotechnology, AIH and AIM is a limited liability company organized under the laws of the State of Delaware.
Mr. Blavatnik is a citizen of the United States of America.
(d)
Title of class of securities:
Common stock, par value $0.0001 per share
(e)
CUSIP Number(s):
517954103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See the responses to Item 9 on the attached cover pages.
(b)
Percent of class:
See the responses to Item 11 on the attached cover pages. The percentages reported in Item 11 on the attached cover pages are based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 7, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See the responses to Item 5 on the attached cover pages.
(ii) Shared power to vote or to direct the vote:
See the responses to Item 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of:
See the responses to Item 7 on the attached cover pages.
(iv) Shared power to dispose or to direct the disposition of:
See the responses to Item 8 on the attached cover pages.
3,185,177 shares of Common Stock are held directly by AI Biotechnology and may also be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH, and (iii) AIH controls all of the outstanding voting interests in AI Biotechnology. Each of the Reporting Persons (other than AI Biotechnology) and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
AI Biotechnology LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
By: Access Industries Management, LLC, its manager; its Executive Vice President, General Counsel/Alejandro Moreno
Date:
08/18/2026
Access Industries Holdings LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
By: Access Industries Management, LLC, its manager; its Executive Vice President, General Counsel/Alejandro Moreno
Date:
08/18/2026
Access Industries Management, LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
Executive Vice President, General Counsel/Alejandro Moreno
Date:
08/18/2026
Len Blavatnik
Signature:
*/s/Alejandro Moreno
Name/Title:
By: Alejandro Moreno/Attorney-in-Fact
Date:
08/18/2026
Comments accompanying signature: * The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.
